# Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Negative Symptoms of Schizophrenia

> **NCT03896945** · PHASE2,PHASE3 · TERMINATED · sponsor: **Otsuka Pharmaceutical Development & Commercialization, Inc.** · enrollment: 136 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Placebo
- **DRUG:** AVP-786

## Key facts

- **NCT ID:** NCT03896945
- **Lead sponsor:** Otsuka Pharmaceutical Development & Commercialization, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-02-15
- **Primary completion:** 2023-05-23
- **Final completion:** 2023-05-23
- **Target enrollment:** 136 (ACTUAL)
- **Why stopped:** Based on the Interim Analysis outcome and recommendation by the DMC, Otsuka approved termination of the study based on futility.
- **Last updated:** 2024-05-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03896945

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03896945, "Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Negative Symptoms of Schizophrenia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03896945. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*